Emerging Trends in Non-Interferon-Based Genotype-Specific Antiviral Agents: Pharmaceutical Perspectives.

Abstract

Hepatitis C virus (HCV) presents a serious global health threat. Initially, the health-care community mainly focused on interferon (IFN)-based therapeutic options to eradicate HCV, but with the passage of time, these applications became unsuitable due to some serious side effects related to the use of IFN. In recent years, research conducted on different phases of HCV's life cycle has opened a new gateway for the use of a direct-acting new generation of anti-HCV agents. Their safer and ultrarapid response has made possible the introduction of triple therapy and use of IFN-free therapeutic treatment strategies. However, the high cost of these successful therapies has raised serious concerns, particularly in low-income countries, and this has forced pharmaceutical scientists to explore more cost-effective IFN-free alternatives for the treatment of HCV. In this article, we have briefly summarized the latest data regarding the research and development of non-IFN-based antiviral agents. The studies mentioned in this article highlight the significance of non-IFN-based direct-acting antiviral (DAA) agents. Economical alternative anti-HCV agents are expected to become available in the near future for better and more cost-effective treatments of HCV.